BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26471796)

  • 1. [Patients with prostate cancer after radical prostatectomy: Stage migration and changes in tumor characteristics from 1998-2012].
    Walther A; Kron M; Klorek T; Gschwend JE; Herkommer K
    Urologe A; 2016 Feb; 55(2):167-75. PubMed ID: 26471796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathological prostate cancer characteristics at radical prostatectomy after population based screening.
    Hoedemaeker RF; Rietbergen JB; Kranse R; Schröder FH; van der Kwast TH
    J Urol; 2000 Aug; 164(2):411-5. PubMed ID: 10893598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database.
    Grossfeld GD; Chang JJ; Broering JM; Li YP; Lubeck DP; Flanders SC; Carroll PR
    J Urol; 2001 Mar; 165(3):851-6. PubMed ID: 11176485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of stage migration and practice changes on high-risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades.
    Fossati N; Passoni NM; Moschini M; Gandaglia G; Larcher A; Freschi M; Guazzoni G; Sjoberg DD; Vickers AJ; Montorsi F; Briganti A
    BJU Int; 2016 May; 117(5):740-7. PubMed ID: 25787671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
    Caster JM; Falchook AD; Hendrix LH; Chen RC
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade.
    Budäus L; Spethmann J; Isbarn H; Schmitges J; Beesch L; Haese A; Salomon G; Schlomm T; Fisch M; Heinzer H; Huland H; Graefen M; Steuber T
    BJU Int; 2011 Oct; 108(8):1256-61. PubMed ID: 21244612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between the preoperative serum prostate specific antigen, Gleason score, and clinical staging with pathological outcome following robot-assisted radical prostatectomy: an Indian experience.
    Singh P; Dogra PN; Gupta NP; Nayyar R; Seth A; Javali TD; Kumar R
    Indian J Cancer; 2011; 48(4):483-7. PubMed ID: 22293265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
    van Oort IM; Schout BM; Kiemeney LA; Hulsbergen CA; Witjes JA
    Eur Urol; 2005 Oct; 48(4):572-6. PubMed ID: 16046051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens.
    Berger AP; Spranger R; Kofler K; Steiner H; Bartsch G; Horninger W
    Prostate; 2003 Oct; 57(2):93-8. PubMed ID: 12949932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Migration of pathological stage after radical prostatectomy to higher risk tumors of relapse: comparative two-center study between 2005 and 2010].
    Beauval JB; Roumiguié M; Doumerc N; Thoulouzan M; Huyghe E; Allory Y; Mazerolles C; de la Taille A; Malavaud B; Rischmann P; Soulié M; Salomon L
    Prog Urol; 2012 Dec; 22(16):1015-20. PubMed ID: 23178098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in indications and oncological outcomes of radical prostatectomy after 2000--data from 1268 Japanese patients treated with radical prostatectomy between 2000 and 2009.
    Mitsuzuka K; Koie T; Narita S; Kaiho Y; Yoneyama T; Tsuchiya N; Kakoi N; Kawamura S; Tochigi T; Ohyama C; Habuchi T; Yamaguchi T; Arai Y
    Jpn J Clin Oncol; 2013 Aug; 43(8):821-6. PubMed ID: 23729494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncologic control obtained after radical prostatectomy in men with a pathological Gleason score ≥ 8: a single-center experience.
    Audenet F; Comperat E; Seringe E; Drouin SJ; Richard F; Cussenot O; Bitker MO; Rouprêt M
    Urol Oncol; 2011; 29(6):602-7. PubMed ID: 19926312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.